Dexamethasone is a type of corticosteroid medication. It is use... - dofaq.co
Dexamethasone is a type of corticosteroid medication. It is use...Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis. In adrenocortical insufficiency, it should be used together with a medication that has greater mineralocorticoid effects such as fludrocortisone. In preterm labor, it may be used to improve outcomes in the baby. It may
The Efficacy of N-Butylphthalide and Dexamethasone Combined with Hyper | DDDT
Elotuzumab Added to Lenalidomide and Dexamethasone Fails to Improve PFS in Multiple Myeloma
Elotuzumab, Lenalidomide, and Dexamethasone as Salvage Therapy for Multiple Myeloma
Ninlaro Combo for New Myeloma Patients Fails to Meet Primary Trial Goal
Cushing's Cutoff Value for Dexamethasone Suppression Tests Established
RRMM Survival Significantly Extended with Xpovio Combo, Trial Shows
Phase I/II Study Shows Promise for Melflufen in Multiple Myeloma
Influence of short-term dexamethasone on the efficacy of 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. dexamethasone on the efficacy of 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. ...
Tobramycin/Dexamethasone Suspension Available for Inflammatory Eye Conditions With Bacterial Infection
2 newer multiple myeloma drugs fall short in bid for wider market
What You Need to Know About the FDA's Approval of Sarclisa for Multiple Myeloma
UK Begins Trial of HIV Medicine, Steroid as Possible COVID-19 Treatments
Multiple Myeloma Survival Not Extended in Empliciti Combo Trial
Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma | Antibodies | News Channels
Network Meta-Analysis of Treatment Regimens for Relapsed/Refractory Multiple Myeloma
Trial of three-agent combination for multiple myeloma misses endpoint
Statistical Significance Not Met With Ixazomib Triplet in Newly Diagnosed Myeloma Trial
Corticosteroids May Reduce Mortality in Patients With ARDS
VTE risk substantial, despite thromboprophylaxis, with lenalidomide-based regimens for multiple myeloma
